Arab Journal of Gastroenterology
Volume 11, Issue 3 , Pages 141-148 , September 2010

Survivin immunohistochemical expression in hepatocellular carcinoma: Correlation with tumour differentiation and proliferation

  • Eiman Adel Hasby

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Dr. Adel Hasby Building, 1 Mohammed Wahdan Street, El Mehalla El Kobra, El Gharbeya Governorate, Egypt. Tel.: +20 40 224 5501;mobile: +20 12 29 48785.
    • ,
  • Mohammed Alaa Mokhtar

Received 31 January 2010 ,Accepted 3 July 2010.

References 

  1. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35(3):519–524
  2. Katyal S, Oliver JH, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216(3):698–703
  3. Lee WC, Jeng LB, Chen MF. Estimation of prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg. 2002;89(3):311–316
  4. Mamori S, Asakura T, Ohkawa K, et al. Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition. World J Gastroenterol. 2007;13(40):5306–5311
  5. Ye CP, Qiu CZ, Huang ZX, et al. Relationship between survivin expression and recurrence and prognosis in hepatocellular carcinoma. World J Gastroenterol. 2007;13(46):6264–6268
  6. Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol. 2006;27(5):244–250
  7. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell. 1997;88(3):347–354
  8. Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: mechanisms and relevance in cancer. Ann Hematol. 2005;84(10):627–639
  9. Altieri DC. New wirings in the survivin networks. Oncogene. 2008;27(48):6276–6284
  10. Tarnawski A, Pai R, Chiou SK, et al. Rebamipide inhibits gastric cancer growth by targeting survivin and aurora-B. Biochem Biophys Res Commun. 2005;334(1):207–212
  11. Wakana Y, Kasuya K, Katayanagi S, et al. Effect of survivin on cell proliferation and apoptosis in gastric cancer. Oncol Rep. 2002;9(6):1213–1218
  12. Kania J, Konturek SJ, Marlicz K, et al. Expression of survivin and caspase-3 in gastric cancer. Dig Dis Sci. 2003;48(2):266–271
  13. Zhu XD, Lin GJ, Qian LP, et al. Expression of survivin in human gastric carcinoma and gastric carcinoma model of rats. World J Gastroenterol. 2003;9(7):1435–1438
  14. Zhu H, Chen XP, Zhang WG, et al. Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma. World J Gastroenterol. 2005;11(25):3855–3859
  15. Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 2006;8(6):216
  16. Depowski PL, Rosenthal SI, Brien TP, et al. Topoisomerase II alpha expression in breast cancer: correlation with outcome variables. Mod Pathol. 2000;13(5):542–547
  17. Lynch BJ, Guinee DG, Holden JA. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol. 1997;28(10):1180–1188
  18. Nakopoulou L, Lazaris AC, Kavantzas N, et al. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology. 2000;68(3):137–143
  19. Jarvinen TA, Kononen J, Pelto Huikko M, et al. Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy and c-erbB2 overexpression in breast cancer. Am J Pathol. 1996;148(6):2073–2082
  20. Pawlik TM, Gleisner AL, Anders RA, et al. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg. 2007;245(3):435–442
  21. Fields AC, Cotsonis G, Sexton D, et al. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters and outcome. Mod Pathol. 2004;17(11):1378–1385
  22. Willman JH, Holden JA. Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant and malignant lesions of the prostate. Prostate. 2000;42(4):280–286
  23. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267(5203):1456–1462
  24. Saikumar P, Dong Z, Mikhailov V, et al. Apoptosis: definition, mechanisms and relevance to disease. Am J Med. 1999;107(5):489–506
  25. Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res. 1999;248(1):30–43
  26. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by fas (CD95), bax, caspases and anticancer drugs. Cancer Res. 1998;58(23):5315–5320
  27. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40(4):1117–1123
  28. Asanuma K, Moriai R, Yajima T, et al. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res. 2000;91(11):1204–1209
  29. Asanuma K, Kobayashi D, Furuya D, et al. A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res. 2002;93(9):1057–1062
  30. Ikeguchi M, Ueda T, Sakatani T, et al. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol. 2002;11(1):33–40
  31. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3(1):46–54
  32. Li F. Survivin study: what is the next wave?. J Cell Physiol. 2003;197(1):8–29
  33. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6(1):127–134
  34. Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001;92(2):271–278
  35. Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95(2):92–95
  36. Nakamura M, Tsuji N, Asanuma K, et al. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients. Cancer Sci. 2004;95(1):44–51
  37. Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58(22):5071–5074
  38. Sarela AI, Macadam RC, Farmery SM, et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut. 2000;46(5):645–650
  39. Ito T, Shiraki K, Sugimoto K, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 2000;31(5):1080–1085
  40. Moon WS, Tarnawski AS. Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth?. Hum Pathol. 2003;34(11):1119–1126
  41. Morinaga S, Nakamura Y, Ishiwa N, et al. Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep. 2004;12(6):1189–1194
  42. Grabowski P, Kuhnel T, Muhr Wilkenshoff F, et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer. 2003;88(1):115–119
  43. Wong N, Yeo W, Wong WL, et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 2009;124(3):644–652
  44. Pizem J, Marolt VF, Luzar B, et al. Proliferative and apoptotic activity in hepatocellular carcinoma and surrounding non-neoplastic liver tissue. Pflugers Arch. 2001;442(6 Suppl 1):R174-6
  45. Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene. 2000;19(29):3225–3234
  46. Li F, Yang J, Ramnath N, et al. Nuclear or cytoplasmic expression of survivin: what is the significance?. Int J Cancer. 2005;114(4):509–512

PII: S1687-1979(10)00083-3

doi: 10.1016/j.ajg.2010.07.001

Arab Journal of Gastroenterology
Volume 11, Issue 3 , Pages 141-148 , September 2010

Article Tools

* Image Usage & Resolution